专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110307427A1 Molecular markers predicting response to adjuvant therapy, or disease progression, in breast cancer 审中-公开
标题翻译：预测乳腺癌中辅助治疗或疾病进展的反应的分子标记
公开(公告)号：US20110307427A1
公开(公告)日：2011-12-15
申请号：US13199068
申请日：2011-08-18
申请人： Steven Linke , Troy Bremer , Comelius Diamond
发明人： Steven Linke , Troy Bremer , Comelius Diamond
IPC分类号： G06N5/02 , G06F15/18
CPC分类号： G01N33/57415 , G01N2800/52 , G01N2800/56 , G16B20/00 , G16B25/00 , G16B40/00
摘要： Predicting response to adjuvant therapy or predicting disease progression in breast cancer is realized by (1) first obtaining a breast cancer test sample from a subject; (2) second obtaining clinicopathological data from said breast cancer test sample; (3) analyzing the obtained breast cancer test sample for presence or amount of (a) one or more molecular markers of hormone receptor status, one or more growth factor receptor markers, (b) one or more tumor suppression/apoptosis molecular markers; and (c) one or more additional molecular markers both proteomic and non-proteomic that are indicative of breast cancer disease processes; and then (4) correlating (a) the presence or amount of said molecular markers and, with (b) clinicopathological data from said tissue sample other than the molecular markers of breast cancer disease processes. A kit of (1) a panel of antibodies; (2) one or more gene amplification assays; (3) first reagents to assist said antibodies with binding to tumor samples; (4) second reagents to assist in determining gene amplification; permits, when applied to a breast cancer patient's tumor tissue sample, (A) permits observation, and determination, of a numerical level of expression of each individual antibody, and gene amplification; whereupon (B) a computer algorithm, residing on a computer can calculate a prediction of treatment outcome for a specific treatment for breast cancer, or future risk of breast cancer progression.
摘要翻译：预测乳腺癌辅助治疗或预测疾病进展的反应是通过以下方式实现的：（1）首先从受试者获得乳腺癌试验样品; （2）第二次从所述乳腺癌试验样品获得临床病理资料; （3）分析获得的乳腺癌试验样品的存在或量（a）一种或多种激素受体状态的分子标记，一种或多种生长因子受体标记，（b）一种或多种肿瘤抑制/凋亡分子标记; 和（c）指示乳腺癌疾病过程的一种或多种另外的蛋白质组学和非蛋白质组学的分子标记物; 然后（4）将（a）所述分子标记的存在或量与（b）来自所述组织样本的除了乳腺癌疾病过程的分子标记之外的临床病理学数据相关联。（1）一组抗体的试剂盒; （2）一个或多个基因扩增测定; （3）协助所述抗体与肿瘤样品结合的第一试剂; （4）辅助确定基因扩增的第二试剂; 允许当应用于乳腺癌患者的肿瘤组织样品时，（A）允许观察和确定每个单独抗体的数字表达水平和基因扩增; 因此（B）驻留在计算机上的计算机算法可以计算乳腺癌特异性治疗或乳腺癌进展的未来风险的治疗结果的预测。

IPRDB

热门服务

关于我们

友情链接

联系方式